quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:20:05·50d
INSIDERFiling
Ventyx Biosciences Inc. logo

CHIEF SCIENTIFIC OFFICER Nuss John returned 489,481 shares to the company, closing all direct ownership in the company (SEC Form 4)

VTYX· Ventyx Biosciences Inc.
Health Care
Original source

Companies

  • VTYX
    Ventyx Biosciences Inc.
    Health Care

Recent analyst ratings

  • Nov 5UpdateH.C. Wainwright$18.00
  • Mar 12UpdateOppenheimer$12.00
  • Mar 12UpdateWells Fargo$16.00
  • Nov 7UpdateMorgan Stanley$6.00
  • Nov 7UpdateOppenheimer-
  • Nov 7UpdateH.C. Wainwright-

Related

  • SEC38d
    SEC Form 15-12G filed by Ventyx Biosciences Inc.
  • SEC46d
    SEC Form EFFECT filed by Ventyx Biosciences Inc.
  • SEC46d
    SEC Form EFFECT filed by Ventyx Biosciences Inc.
  • SEC50d
    Amendment: SEC Form SCHEDULE 13D/A filed by Ventyx Biosciences Inc.
  • INSIDER50d
    Senior VP, Finance Gonzales Roy returned 5,313 shares to the company, closing all direct ownership in the company (SEC Form 4)
  • INSIDER50d
    Director Subramaniam Somu returned 3,337,495 shares to the company (SEC Form 4)
  • INSIDER50d
    SEC Form 4 filed by Director White William Richard
  • INSIDER50d
    SEC Form 4 filed by Chief Operating Officer Moore Matthew Richard
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022